This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in.

Slides:

Advertisements

Similar presentations

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.

Advertisements

Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer

Finding the Right Fit: Personalizing Treatment in Metastatic Castration-Resistant Prostate Cancer.

Bladder Cancer: A New Era in Treatment

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

State of the Art in BRCA-Mutated Ovarian Cancer

New Tracers for Prostate Cancer Imaging

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

New Psoriasis Treatments

Updates and Insights on the Medical Science of Prostate Cancer

Improving Survival in Glioblastoma Multiforme

T-Cell Exhaustion: Can We Overcome It in Cancer?

This program will include a discussion of off-label treatment and devices and investigational agents and devices not approved by the FDA for use in the.

Applying New Data in Practice:

Progression After Cancer Immunotherapy in Advanced NSCLC

Jaden D. Evans, MD, Krishan R

New Standards of Care in ALK-Translocated Advanced NSCLC

Unmet Needs in Schizophrenia

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Navigating the Data and Evolving Our Approach

Expanding Treatment Horizons in Head and Neck Cancer: TRK Inhibitors

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Addressing Disease Burden in Asthma

Optimizing Management of Advanced Bladder Cancer

Updates in Detection and Management of BCRPC

Individualizing Care in Ovarian Cancer

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

Postpartum Depression

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Evaluating Next-Generation BTK Inhibitors

Case Studies in Unresectable Hepatocellular Carcinoma

Hyperhidrosis Is Burdensome!

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Ask the Experts.

Nat. Rev. Urol. doi: /nrurol

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

Personalizing Management in the Care of Patients With Advanced Sarcoma

Evolving Concepts in the Management of Head and Neck Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Parkinson Disease Psychosis

Getting to Grips With the Science of CGRP and Migraine

Advances in Immunotherapy for Peanut Allergy

Immune Checkpoint Inhibitors in Lung Cancer

Locally Advanced Lung Cancer

Guide to Atopic Dermatitis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Molecular Testing in Ovarian Cancer: Is the Time Now?

Patient Questions and Expert Answers in Psoriasis:

Biomarker Testing: Harnessing All Sides of the Tumor Microenvironment

Evaluating BTK Inhibitors in CLL

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

Optimizing Joint Health in Hemophilia

2017 Parkinson Disease.

Novel Concepts in the Management of RCC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

From Adjuvant to Metastatic in Melanoma

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

VKA Reversal and LVADs.

CDK4/6 Inhibitors.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

Presentation transcript:

Biochemically Recurrent Prostate Cancer: Optimizing Detection and Management

This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Prostate Cancer Incidence and Significance of BCR

Defining BCR After RP

Defining BCR After RT

Clinical Implications of a Rising PSA

Mortality After BCR Following RP Retrospective Cohort Study

Current Management of BCR Prostate Cancer

Diagnostic Evaluation of Patients With BCR

NaF-PET/CT An Alternative to Conventional Scanning

PET in BCR Prostate Cancer

PET Radiopharmaceuticals Approved or Under Evaluation in Prostate Cancer

Recommendations for PET/CT in Men With BCR

Choline: Overview

Use of 11C-Choline-PET/CT in Patients With BCR

Example of 11C-Choline-PET/CT in a Patient With BCR

11C-Choline-PET/CT Sensitivity by PSA Level

18F-Fluciclovine (FACBC): Overview

18F-Fluciclovine-PET/CT in BCR Prostate Cancer BED-001 Study

Prospective Study of 18F-Fluciclovine-PET/CT vs 11C-Choline-PET/CT in BCR Prostate Cancer

Example of 18F-Fluciclovine-PET/CT

18F-Fluciclovine-PET/CT Scan Showing Metastatic Prostate Cancer 2 Months Later

PSMA: An Investigational PET Imaging Target

Example of 18F-DCFPyL PET/CT Imaging in a Patient With BCR Prostate Cancer

Example of 68Ga PSMA PET/CT Imaging

Targeting Oligometastatic Prostate Cancer

Conclusions

Abbreviations

Abbreviations (cont)